Roivant Sciences Ltd.

ROIV · Healthcare

$34.52

Capitalización: 24.93B USDRendimiento por dividendo: —
Advance¿Es buen momento para comprar Roivant Sciences Ltd.? Pregunta a Copenvest AIObtén una lectura Advance con IA sobre timing, riesgo y qué hacen los inversores rastreados.Preguntar a Copenvest AI

Cargando gráfico…

Noticias

Últimos titulares de esta acción

MarketBeat28 ago 2026, 15:02

Roivant Sciences Wins FDA Approval for LISRAYA in Dermatomyositis, Launches Immediately

MT Newswires27 ago 2026, 19:58

Roivant Sciences Gets FDA Approval for LISRAYA in Dermatomyositis; Shares Rise

GlobeNewswire27 ago 2026, 19:29

Roivant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S.

GlobeNewswire27 ago 2026, 19:28

Priovant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S.